| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4308294 | Surgery | 2012 | 9 Pages |
Abstract
Combined PIK3CA and KRAS small interfering RNA treatments offer an effective therapy against colorectal cancer cells with coexisting mutations in both pathways. Decreased 4E-BP1 phosphorylation correlates with increased apoptosis and may provide a biomarker indicative of treatment success. In addition, small interfering RNA directed to PIK3CA and KRAS may be used to enhance the effects of current chemotherapy.
Related Topics
Health Sciences
Medicine and Dentistry
Surgery
Authors
Joseph D. MD, Victoria A. BS, Yekaterina Y. PhD, Piotr G. MD, W. Conan MD, Chi PhD, Tianyan PhD, B. Mark MD,